Fourth Quarter Financial Results (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | 12 Months Ended | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 30, 2020 |
Sep. 11, 2020 |
Jun. 17, 2020 |
Feb. 20, 2020 |
Nov. 01, 2019 |
Sep. 06, 2019 |
Jun. 20, 2019 |
Feb. 21, 2019 |
Nov. 02, 2018 |
Sep. 07, 2018 |
Jun. 14, 2018 |
Feb. 15, 2018 |
Dec. 31, 2020 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Dec. 31, 2018 |
||||
| Quarterly Financial Information Disclosure [Abstract] | |||||||||||||||||||
| Net revenues | $ 13,858 | $ 45,804 | $ 33,266 | $ 32,753 | |||||||||||||||
| Gross margin | 9,174 | ||||||||||||||||||
| Net earnings attributable to AbbVie Inc. | $ 36 | [1] | $ 4,616 | $ 7,882 | $ 5,687 | ||||||||||||||
| Basic earnings per share (in dollars per share) | $ 0.01 | $ 2.73 | $ 5.30 | $ 3.67 | |||||||||||||||
| Diluted earnings per share (in dollars per share) | 0.01 | 2.72 | 5.28 | 3.66 | |||||||||||||||
| Cash dividends declared per common share (in dollars per share) | $ 1.30 | $ 1.18 | $ 1.18 | $ 1.18 | $ 1.18 | $ 1.07 | $ 1.07 | $ 1.07 | $ 1.07 | $ 0.96 | $ 0.96 | $ 0.96 | $ 1.30 | $ 4.84 | $ 4.39 | $ 3.95 | |||
| After-tax cost related to change in fair value of contingent consideration liabilities | $ 4,700 | $ 5,753 | $ 3,091 | $ 49 | |||||||||||||||
| After-tax benefit due to impacts related to tax law changes | $ 1,500 | ||||||||||||||||||
| |||||||||||||||||||
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax law changes. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Aggregate dividends declared during the period for each share of common stock outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|